<DOC>
	<DOCNO>NCT00908336</DOCNO>
	<brief_summary>Erlotinib demonstrate efficacy single agent patient NSCLC addition erlotinib chemotherapy achieve good result general population . However , several preclinical phase I study show sequential treatment erlotinib chemotherapy could avoid possible negative interaction drug administrate concomitantly , therefore , could improve benefit combination therapy . This study investigate intermittent treatment chemotherapy drug , docetaxel , erlotinib could achieve clinical benefit .</brief_summary>
	<brief_title>Erlotinib Docetaxel Patients With Locally Advanced Metastatic Non-Small Cell Lung Cancer ( NSCLC ) After Failure One Chemotherapy Regimen</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Written inform consent . Age &gt; = 18 year . Histologically cytologically document inoperable , locally advanced ( stage IIIb malignant pleural pericardial effusion ) metastatic ( Stage IV ) NSCLC . Patients fail one prior chemotherapy treat advance disease candidate receive second line treatment . ECOG PS 02 . Adequate hematological function : hemoglobin = &gt; 9 g/dl ; neutrophil count = &gt; 1.5 x 10 ( 9 ) /l ; platelet count = &gt; 100 x 10 ( 9 ) /l . Adequate liver function : Bilirubin &lt; = 1,5 x ULN ; AST ALT &lt; = x 3 ULN hepatic metastasis &lt; =5 x ULN hepatic metastasis ; Alkaline phosphatase &lt; =5 x UNL except hepatic metastasis . Adequate renal function : Calculated creatinine clearance = &gt; 40 mL/min ( Cockroft Gault ) serum creatinine &lt; = 1.5 x ULN . Patient able meet requirement study accessible correct followup . Oral swallow capability . Previous treat one chemotherapeutic treatment NSCLC Concomitant treatment another drug investigation . Pregnancy lactation . Fertile woman must provide negative result pregnancy test ( serum urine ) within 7 day prior study treatment start . In addition , must use effective method contraception ( oral contraceptive , intrauterine device , barrier method contraception , together spermicidal jelly surgical sterilization ) study . Evidence disease , metabolic neurological dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug patient high risk treatment complication . Contraindication use erlotinib docetaxel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Carcinoma , Non-Small Cell</keyword>
	<keyword>Lung Neoplasms</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>